Notizia - Recent Pharma, Healthcare and Biotech Happenings

AbbVie aims for best-in-class psoriasis prospect The last few years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class product may still be on its way. AbbVie prospect risankizumab showed it could bring 47% of patients to complete skin clearance by week 16 of treatment in a phase 3 study, topping placebo, which hit that benchmark in just 1% of patients. And of those who did achieve clear or almost clear skin, 87% were still in that group at the one-year mark. The AbbVie wannabe produced a slightly higher proportion of patients hitting key benchmarks on the skin-clearance scale, and with less-frequent dosing than the J&J produc...